Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
StockNews.AI · 3 hours
AI Summary
Shattuck Labs will host an investor call and webcast on June 8, 2026 to disclose Phase 1 data for SL-325, a DR3-blocking antibody. The presentation will cover safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics and immunogenicity, along with a pipeline update. Positive safety and PK signals could provide near-term upside for STTK, while weak results may cap any rally.
Sentiment Rationale
Upcoming Phase 1 data can be a meaningful catalyst, but outcomes are uncertain and microcap biotechs often exhibit volatility regardless of direction. Historical biotech data releases lead to sharp moves only when results deviate from expectations.
Trading Thesis
Near-term STTK upside possible if Phase 1 data are favorable; downside risk if data disappoints, within days of the June 8 event.
Market-Moving
- Catalyst: Phase 1 SL-325 data presentation on June 8, 2026.
- Live webcast and 30-day replay may trigger intraday volatility.
- Positive safety/PK signals could drive short-term STTK upside.
Key Facts
- Shattuck to present Phase 1 SL-325 data on June 8, 2026.
- Data to include safety, tolerability, PK, receptor occupancy, PD.
- SL-325 targets DR3/TL1A; potentially first-in-class, Fc-silenced antibody.
- Offices in Austin and Durham support DR3 program.
- Live webcast with ~30-day replay after event.
Companies Mentioned
- Shattuck Labs, Inc. (STTK): Phase 1 data presentation for SL-325 could drive near-term stock volatility.
Research Analysis
Category: Research Analysis. Event centers on an early-stage biotech data milestone and pipeline update, with potential near-term stock implications for STTK depending on data signals.